IDIQ for pharmaceutical products for cder research studies. Includes brand name and/or generic pharmaceuticals to include small molecule and peptide therapeutics, drug-device combination products, and…
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75F40126D00023
- Awardee
-
We Pharma, Inc. UEI EWAMVJSFNK29
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Pharmaceutical Products for CDER Research Studies - IDIQ Pre-Solicitation · 75F40126Q132721 · Posted Mar 5, 2026
- Last date to order 2% complete
- IDV ceiling
- $4,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Food and Drug Administration awarded an indefinite-delivery contract to We Pharma, Inc. with a ceiling of $4 million on September 15, 2026, as a single-award vehicle. The contract carries no set-aside designation and runs through September 14, 2031.
The IDIQ procures brand name and generic pharmaceuticals for the Center for Drug Evaluation and Research, including small molecule and peptide therapeutics, drug-device combination products, and contrast agents to support CDER laboratory, animal, and human research initiatives. The contract is classified under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6505 (Drugs and Biologicals).
We Pharma, Inc. is a small disadvantaged business structured as a limited liability company and located in Morrisville, North Carolina. The company operates as WEP Clinical and has provided pharmaceutical products exclusively to the FDA through prior federal contract awards ranging from $100,000 to $2 million, supporting research initiatives including the Generic Drug User Fee Amendments program and the Office of Pharmaceutical Quality Research. The company maintains a pharmaceutical pricing list updated annually and provides emergency overnight delivery capabilities.
The underlying market research, posted March 5, 2026, identified approximately 100 pharmaceutical products spanning multiple therapeutic categories—including controlled substances, biologics, injectables, inhalants, ophthalmic preparations, and intrauterine devices—with specific formulations, strengths, package sizes, and NDC numbers. The forecast included both brand names (ABRAXANE, ADVAIR DISKUS, NEXIUM, SPIRIVA RESPIMAT, VICTOZA) and their generic equivalents to be supplied on an as-needed basis.
Description
IDIQ for pharmaceutical products for cder research studies. Includes brand name and/or generic pharmaceuticals to include small molecule and peptide therapeutics, drug-device combination products, and contrast agents. EO 14398
Quick answers
Who was awarded contract 75F40126D00023?
75F40126D00023 was awarded to We Pharma, Inc. by Food and Drug Administration (Department of Health and Human Services) on September 15, 2026.
How much is contract 75F40126D00023 worth?
75F40126D00023's own ceiling is $4,000,000.
Who can order from contract 75F40126D00023?
75F40126D00023 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75F40126D00023 competed?
The extent of competition for 75F40126D00023 was competed under sap. The government received 2 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV